La cadena de opciones muestra datos clave de las opciones de acciones de Rhythm Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Rhythm Pharmaceuticals..

Rhythm Pharmaceuticals (NASDAQ:RYTM) Bolsa, Cadena de Opciones

Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals Inc

WIIM

RYTM

Rhythm Pharmaceuticals shares are trading higher after multiple firms maintained a Buy rating on the stock and raised their respective price targets.

<p>Canaccord Genuity  analyst Whitney Ijem   maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and raises the price target from $77 to $80.</p>


News

Price Target

Analyst Ratings

Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $80

<p>TD Cowen  analyst Phil Nadeau   maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and raises the price target from $55 to $65.</p>


TD Cowen Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $65

<p>Needham  analyst Joseph Stringer   maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and raises the price target from $55 to $64.</p>


Needham Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $64

<p>Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.82) by 10.98 percent. This is a 3.95 percent increase over losses of $(0.76) per share from the same period last year.  The company reported quarterly sales of $33.251 million which beat the analyst consensus estimate of $32.517 million by 2.26 percent.  This is a 47.76 percent increase over sales of $22.504 million the same period last year.</p>


Earnings

Earnings Beats

Rhythm Pharmaceuticals Q3 2024 GAAP EPS $(0.73) Beats $(0.82) Estimate, Sales $33.251M Beat $32.517M Estimate

<p>Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) will release its quarterly earnings report on Tuesday, 2024-11-05. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Rhythm Pharmaceuticals to report an <strong>earnings per share</strong> (EPS) of $-0.81.</p>
<p>The announcement from Rhythm Pharmaceuticals is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Past Earnings Performance</h3>
<p>The company's EPS beat by $0.16 in the last quarter, leading to a 1.09% drop in the share price on the following day.</p>
<p>Here's a look at Rhythm Pharmaceuticals's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.71</td>
<td>-2.16</td>
<td>-0.7</td>
<td>-0.76</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.55</td>
<td>-2.35</td>
<td>-0.7</td>
<td>-0.76</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-1.0%</td>
<td>2.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730746932_0_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Rhythm Pharmaceuticals were trading at $49.01 as of November 01. Over the last 52-week period, shares are up 94.77%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Take on Rhythm Pharmaceuticals</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Rhythm Pharmaceuticals.</p>
<p>With 8 analyst ratings, Rhythm Pharmaceuticals has a consensus rating of Buy. The average one-year price target is $61.0, indicating a potential 24.46% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of Iovance Biotherapeutics, Amicus Therapeutics and Apellis Pharmaceuticals, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>The prevailing sentiment among analysts is an Buy trajectory for Iovance Biotherapeutics, with an average 1-year price target of $24.5, implying a potential 50.01% downside.</li>
<li>Amicus Therapeutics is maintaining an Outperform status according to analysts, with an average 1-year price target of $17.4, indicating a potential 64.5% downside.</li>
<li>The prevailing sentiment among analysts is an Neutral trajectory for Apellis Pharmaceuticals, with an average 1-year price target of $61.21, implying a potential 24.89% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
<p>In the peer analysis summary, key metrics for Iovance Biotherapeutics, Amicus Therapeutics and Apellis Pharmaceuticals are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rhythm Pharmaceuticals</td>
<td>Buy</td>
<td>51.28%</td>
<td>$26.13M</td>
<td>-66.51%</td>
</tr>
<tr>
<td>Iovance Biotherapeutics</td>
<td>Buy</td>
<td>12969.75%</td>
<td>$-262K</td>
<td>-13.41%</td>
</tr>
<tr>
<td>Amicus Therapeutics</td>
<td>Outperform</td>
<td>34.04%</td>
<td>$115.41M</td>
<td>-11.93%</td>
</tr>
<tr>
<td>Apellis Pharmaceuticals</td>
<td>Neutral</td>
<td>110.26%</td>
<td>$176.59M</td>
<td>-14.18%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Rhythm Pharmaceuticals ranks at the bottom for Revenue Growth and Gross Profit among its peers. It is also at the bottom for Return on Equity.</p>
<h3>All You Need to Know About Rhythm Pharmaceuticals</h3>
<p>Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.</p>
<h3>Key Indicators: Rhythm Pharmaceuticals's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Rhythm Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>51.28%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-115.42%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-66.51%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Rhythm Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-10.48%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Rhythm Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of <b>0.1</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/RYTM/earnings"><strong>To track all earnings releases for Rhythm Pharmaceuticals visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


What's Next: Rhythm Pharmaceuticals's Earnings Preview

<p>Needham  analyst Joseph Stringer   reiterates Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and maintains $55 price target.</p>


Reiteration

Needham Reiterates Buy on Rhythm Pharmaceuticals, Maintains $55 Price Target

<p>7 analysts have expressed a variety of opinions on Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $61.86, a high estimate of $70.00, and a low estimate of $52.00. This current average has increased by 7.12% from the previous average price target of $57.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729864868_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A comprehensive examination of how financial experts perceive Rhythm Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$64.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$64.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$64.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Wolleben</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$64.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Rhythm Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Rhythm Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Rhythm Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Rhythm Pharmaceuticals's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RYTM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Rhythm Pharmaceuticals analyst ratings.</strong></a></p>
<h2>About Rhythm Pharmaceuticals</h2>
<p>Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.</p>
<h3>Unraveling the Financial Story of Rhythm Pharmaceuticals</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Rhythm Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>51.28%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Rhythm Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-115.42%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Rhythm Pharmaceuticals's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-66.51%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Rhythm Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-10.48%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.1</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Critical Insights From Rhythm Pharmaceuticals Analyst Ratings: What You Need To Know

<p>HC Wainwright &amp; Co.  analyst Raghuram Selvaraju   reiterates Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and maintains $64 price target.</p>


HC Wainwright & Co. Reiterates Buy on Rhythm Pharmaceuticals, Maintains $64 Price Target

Rhythm Pharmaceuticals, Axovia Therapeutics Plan Joint Research Collaboration Designed To Advance Understanding Of Bardet-Biedl Syndrome

<p>Guggenheim  analyst Seamus Fernandez   initiates coverage on Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy rating and announces Price Target of $70.</p>


Initiation

Guggenheim Initiates Coverage On Rhythm Pharmaceuticals with Buy Rating, Announces Price Target of $70

<p>B of A Securities  analyst Tazeen Ahmad   maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Neutral and raises the price target from $48 to $52.</p>


B of A Securities Maintains Neutral on Rhythm Pharmaceuticals, Raises Price Target to $52

<p>During the last three months, 5 analysts shared their evaluations of Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Rhythm Pharmaceuticals, presenting an average target of $60.4, a high estimate of $64.00, and a low estimate of $55.00. Witnessing a positive shift, the current average has risen by 9.82% from the previous average price target of $55.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728302481_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Rhythm Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$64.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$64.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Wolleben</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$64.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$46.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Rhythm Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Rhythm Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Rhythm Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Rhythm Pharmaceuticals's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RYTM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Rhythm Pharmaceuticals analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Rhythm Pharmaceuticals</h2>
<p>Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.</p>
<h3>Breaking Down Rhythm Pharmaceuticals's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Rhythm Pharmaceuticals showcased positive performance, achieving a revenue growth rate of <strong>51.28%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Rhythm Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-115.42%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Rhythm Pharmaceuticals's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-66.51%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Rhythm Pharmaceuticals's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-10.48%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Rhythm Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of <b>0.1</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Navigating 5 Analyst Ratings For Rhythm Pharmaceuticals

<p>During the last three months, 4 analysts shared their evaluations of Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Rhythm Pharmaceuticals and provided 12-month price targets. The average target is $59.5, accompanied by a high estimate of $64.00 and a low estimate of $55.00. Surpassing the previous average price target of $50.50, the current average has increased by 17.82%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726664419_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The standing of Rhythm Pharmaceuticals among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$64.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Wolleben</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$64.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$46.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Rhythm Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Rhythm Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Rhythm Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Rhythm Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RYTM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Rhythm Pharmaceuticals analyst ratings.</strong></a></p>
<h2>Get to Know Rhythm Pharmaceuticals Better</h2>
<p>Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.</p>
<h3>Rhythm Pharmaceuticals's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Rhythm Pharmaceuticals displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>51.28%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Rhythm Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-115.42%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Rhythm Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-66.51%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Rhythm Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-10.48%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.1</strong>, Rhythm Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What 4 Analyst Ratings Have To Say About Rhythm Pharmaceuticals

<p>HC Wainwright &amp; Co.  analyst Raghuram Selvaraju   initiates coverage on Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy rating and announces Price Target of $64.</p>


HC Wainwright & Co. Initiates Coverage On Rhythm Pharmaceuticals with Buy Rating, Announces Price Target of $64

Rhythm Pharmaceuticals shares are trading higher after JMP Securities initiated coverage on the stock with a Market Outperform rating and announced a price target of $64.

<p>JMP Securities  analyst Jonathan Wolleben   initiates coverage on Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Market Outperform rating and announces Price Target of $64.</p>


JMP Securities Initiates Coverage On Rhythm Pharmaceuticals with Market Outperform Rating, Announces Price Target of $64

Rhythm Pharmaceutical shares are trading higher after the company announced FDA acceptance for priority review of supplemental NDA for IMCIVREE.

<p><i>-- Label expansion sought to treat younger children with Bardet-Biedl syndrome or POMC/LEPR deficiency --</i><br /><br />&nbsp;</p>
<p><i>-- FDA sets PDUFA goal date of December 26, 2024 --</i></p>
<p>BOSTON, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for IMCIVREE&#xAE; (setmelanotide), a melanocortin-4 receptor (MC4R) agonist, for the treatment of obesity due to Bardet-Biedl syndrome (BBS) or pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency obesity in children as young as 2 years old. The FDA has granted Priority Review of the sNDA and assigned a Prescription Drug User Fee Act (PDUFA) goal date of December 26, 2024.&nbsp;</p>


Biotech

General

Rhythm Pharmaceuticals Announces FDA Acceptance For Priority Review Of Supplemental NDA For IMCIVREE In Patients As Young As 2 Years Old

Here are the major earnings after the close today

Rhythm Pharmaceuticals GAAP EPS of -$0.73 beats by $0.08, revenue of $33.25M beats by $0.78M

Reports Q3 revenue $33.25M, consensus $32.52M. As of September 30, cash, cash equivalents and short-term investments were approximately $298.4M, as...

Rhythm Pharmaceuticals reports Q3 EPS (73c), consensus (80c)

16:24 EST Rhythm lowers FY24 non-GAAP opex view to $245M-$255M from $250M-$270M Published first on TheFly – the ultimate source for real-time, mark...

Rhythm lowers FY24 non-GAAP opex view to $245M-$255M from $250M-$270M

Rhythm Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation

Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2024 Earnings Call Transcript

In a report released yesterday, Phil Nadeau from TD Cowen maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report), with a price ...

Rhythm Pharmaceuticals: Strong Financial Performance and Pipeline Progress Justify Buy Rating

Rhythm Pharmaceuticals ( ($RYTM) ) has released its Q3 earnings. Here is a breakdown of the information Rhythm Pharmaceuticals presented to its inv...

Rhythm Pharmaceuticals Reports Strong Q3 Revenue Growth

TD Cowen raised the firm's price target on Rhythm Pharmaceuticals (RYTM) to $65 from $55 and keeps a Buy rating on the shares. The firm said the BB...

Rhythm Pharmaceuticals price target raised to $65 from $55 at TD Cowen

Rhythm Pharmaceuticals (RYTM) has disclosed a new risk, in the Share Price & Shareholder Rights category. Rhythm Pharmaceuticals faces a significan...

Rhythm Pharmaceuticals' Common Stock Faces Risks from Convertible Preferred Stock Supremacy

AVNW

BBAI

BCSF

CGBD

CPNG

EOSE

EXAS

GMED

GPOR

IGIC

IRBT

JKHY

LAAC

LUMN

MASI

MCHP

MEGEF

MGNX

MRCY

NCMI

PAAS

PAYS

QLYS

RARE

RVLV

RYAM

SMCI

SNDX

STKL

TFPM

TRVG

TSLX

WTTR

Press Releases

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September

Health Care

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old

Comments

Rhythm Pharmaceuticals

Rhythm Pharmaceuticals (RYTM) Opciones

Rhythm Pharmaceuticals (NASDAQ:RYTM) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL